Brief: Tg Therapeutics Announces Issuance Of Permanent J-Code For Briumvi® (Ublituximab-Xiiy) From Centers For Medicare And Medicaid Services
27/04/2023 14:01
TG Therapeutics Inc TGTX.O :
* TG THERAPEUTICS ANNOUNCES ISSUANCE OF PERMANENT J-CODE FOR
BRIUMVI® (UBLITUXIMAB-XIIY) FROM CENTERS FOR MEDICARE AND
MEDICAID SERVICES
* TG THERAPEUTICS INC- UNDER HEALTHCARE COMMON PROCEDURE
CODING
SYSTEM (HCPCS), BRIUMVI J-CODE (J2329) WILL BECOME EFFECTIVE
JULY 1, 2023
Source text for Eikon: ID:nGNX2Gcnkx
Further company coverage: TGTX.O
Recent news on TG Therapeutics
See all newsTG Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Tg Therapeutics Reports Second Quarter 2026 Financial Results And Raises Briumvi® Revenue Guidance
TG Therapeutics Q2 product revenue rises 70% on BRIUMVI sales
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj
U.S. STOCKS ON THE MOVE-Cleveland-Cliffs, Ciena Corp, Nokia Oyj